Volume 8, Issue 2, June 2020, Page: 45-50
Immunotherapy Related Adverse Events Predict Treatment Response
Diana Maslov, Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, the United States; Ochsner Clinical School, University of Queensland, New Orleans, the United States
Katharine Thomas, Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, the United States; Ochsner Clinical School, University of Queensland, New Orleans, the United States; Department of Hematology Oncology, Louisiana State University Health Sciences Center, New Orleans, the United States
Victoria Simenson, Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, the United States
Caitlin Sullivan, Ochsner Clinical School, University of Queensland, New Orleans, the United States; Department of Internal Medicine, Louisiana State University Health Sciences Center, New Orleans, the United States
Alaa Mohammed, Center for Outcomes and Health Services Research, Ochsner Clinic Foundation, New Orleans, the United States
Jessica Boyce, Ochsner Clinical School, University of Queensland, New Orleans, the United States
Marc Matrana, Department of Hematology/Oncology, Ochsner Cancer Institute, New Orleans, the United States
Received: May 17, 2020;       Accepted: May 28, 2020;       Published: Jun. 9, 2020
DOI: 10.11648/j.jctr.20200802.13      View  320      Downloads  174
Abstract
Immunotherapy blocks immunoinhibitory pathways and allows for reversal of immunosuppression caused by malignant tumors. Immunotherapy can cause immune-related adverse events (IrAE) including rash, pneumonitis, colitis endocrinopathy, nephritis, adrenal insufficiency, hepatitis, and uveitis. Limited data exist to predict which patients will have the greatest response to therapy and if there is a correlation between IrAE and immunotherapy effectiveness. The aim of this study was to determine the relationship between IrAE and immunotherapy efficacy. A retrospective medical records review was collected of patients with metastatic cancer who received immunotherapy. Data included demographics, Eastern Cooperative Oncology Group Performance Status, imaging, time on treatment, best response, disease progression, and presence or absence of IrAE while on treatment. Treatment response was analyzed using the Response Evaluation Criteria in Solid Tumors guideline, version 1.1. Overall survival probabilities were calculated by the Kaplan-Meier survival method. 456 patients were included for analysis, 175 (38.4%) had an IrAE while on immunotherapy. The development of IrAE correlated with response rate for complete response, partial response, and overall response rate. A significant increase in overall survival was also seen. The presence of IrAE may be a potential predictive indicator for treatment response to immune checkpoint inhibitors.
Keywords
Immunotherapy, Adverse Events, Neoplasms, Immunology
To cite this article
Diana Maslov, Katharine Thomas, Victoria Simenson, Caitlin Sullivan, Alaa Mohammed, Jessica Boyce, Marc Matrana, Immunotherapy Related Adverse Events Predict Treatment Response, Journal of Cancer Treatment and Research. Vol. 8, No. 2, 2020, pp. 45-50. doi: 10.11648/j.jctr.20200802.13
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
J. Van den Bulk, E. M. E. Verdegaal, N. F. C. C. de Miranda. “Cancer immunotherapy: broadening the scope of targetable tumours.” Open Biol, vol. 8, pp. 6, Jun 2018.
[2]
M. D. Hellmann, T. E. Ciuleanu, A. Pluzanski, J. S. Lee, G. A. Otterson, C. Audigier-Valette, E. Minenza, H. Linardou, S. Burgers, P. Salman, H. Borghaei, S. S. Ramalinga. “Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden,” N Engl J Med, vol. 378, pp. 2093-2104, May 2018.
[3]
J. M. Michot, C. Bigenwald, S. Champiat, M. Collins, F. Carbonnel, S. Postel-Vinay, A. Bardelou, A. Varga, R. Bahleda, A. Hollebecque, C. Massard, A. Fuerea, V. Ribrag, J. P. Armand, N. Amellal, E. Angevin, N. Noel, C. Boutros, C. Mateus, C. Robert, J. C. Soria, A. Marabelle, O. Labotte. “Immune-related adverse events with immune checkpoint blockade: A comprehensive review,” Eur J, vol. 54, pp. 139-148, Feb 2016.
[4]
P. A. Ascierto, R. Addeo, G. Carteni, B. Danieelee, M. De Larentis, G. P. Ianniello, A. Morabito, G. Palmieri, S. Pepe, F. Perrone, S. Pignata, V. Montesarchio. “The role of immunotherapy in solid tumors: report from Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014,” J Transl Med, vol. 12, pp. 291, Oct 2014.
[5]
M. Robainas, R. Otano, S. Bueno, S. Ait-Oudhia. “Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy,” Onco Targets Ther, vol. 10, 1803-1807, Mar 2017.
[6]
Mechanism of Action. OPDIVO® (Nivolumab) Restores Active T-Cell Response Directed at the Tumor to Induce an Anti-Tumor Immune Response. Available online: Opdivohcp.com www.opdivohcp.com/advanced-renal-cell-carcinoma/how-opdivo-works/mechanism-of-action. Accessed 05 May 2019.
[7]
Q. Wang, R. Xu. “Immunotherapy-related adverse events (IrAEs): Extraction from FDA drug labels and comparative analysis,” JAMIA Open vol. 1, pp. 173-178, April 2019.
[8]
M. A. Couey, R. B. Bell, A. A. Patel, M. C. Romba, M. R. Crittenden, B. D. Curti, W. J. Urba, R. S. Leidner. “Delayed immune-related events (DIRE) after discontinuatioin of immunotherapy: diagnostic hazard of autoimmunity at a distance,” J. immunotherapy cancer, vol. 7, pp. 165, Jul 2019.
[9]
M. E. Suarez-Almazor, S. T. Kim, N. Abdel-Wahab, A. Diab, “Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer,” Arthritis Rheumatol, vol. 69, issue 4, pp. 687-699, Apr 2017.
[10]
J. M. Bourke, M. O’Sullivan, M. A. Khattak. “Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors),” Med J Aust, vol. 205, issue 9, pp. 418-424, Nov 2016.
[11]
E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij. “New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1),” Eur J Cancer, vol. 45, issue 2, pp. 228-247, Jan 2009.
[12]
H. Ishihara, T. Takagi, T. Kondo, C. Homma, H. Tachibana, H. Fukuda, K. Yoshida, J. Iizuka, H. Kobayashi, H. Okumi, H. Ishida, K. Tanabe. “Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab,” Urol Oncol, vol. 37, issue 6, pp. e21-e355. e29.6, Jun, 2019.
[13]
T. Fujii, R. R. Colen, M. A. Bilen, K. R. Hess, J. Hajjar, M. E. Suarez-Almazor, A. Alshawa, D. S. Hong, A. Tsimberidou, F. Janku, J. Gong, B. Stephen, V. Subbiah, S. A. Piha-Paul, S. Fu, P. Sharma, T. Mendoza, A. Patel, S. Thirumurthi, A. Sheshadri, F. Meric-Bernstam, A. Naing. “Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience,” Invest New Drugs, vol. 36, issue 4, pp. 638-646, Aug 2018.
[14]
A. M. Ramos-Levi, J. Rogado, J. M. Sanchez-Torres, R. Colomer, M. Marazuela. “Nivolumab-induced thyroid dysfunction in patients with lung cancer,” Endocrinol Diabetes Nutr, vol. 66, issue 1, pp. 26-34, Jan 2019.
[15]
J. Rogado, J. M. Sanchez-Torres, N. Romero-Laorden, A. I. Ballesteros, V. Pacheco-Barcia, A. Ramos-Levi, R. Arranz, A. Lorenzo, P. Gullon, O. Donnay, M. Adrados, P. Costas, J. Aspa, A. Alfranca, R. Mondejar, R. Colomer. “Immune-related adverse events predict the therapeutic efficacy of ati-PD-1 antibodies in cancer patients,” Eur J Cancer, vol. 109, pp. 21-27, Mar 2019.
[16]
C. K. M. Lee, S. Li, D. C. Tran, G. A. Zhu, J. Kim, B. Y. Kwong, A. L. S. Chang. “Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study,” J Am Acad Dermatol, vol. 79, issue 6, pp. 1047-1052, Dec 2018.
[17]
K. Sato, H. Akamatsu, E. Murakami, S. Sasaki, K. Kanai, A. Hayata, N. Tokudome, K. Akamatsu, Y. Koh, H. Ueda, M. Nakanishi, N. Yamamoto. “Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treatment with nivolumab,” Lung Cancer, vol. 115, pp. 71-74, Jan 2018.
[18]
J. Judd, M. Zibelman, E. Handorf, J. O’Neill, C. Ramamurthy, S. Bentota, J. Doyle, R. G. Uzzo, J. Bauman, H. Borghaei, E. R. Plimack, R. Mehra, D. M. Geynisman. “Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors,” Oncologist, vol. 22, issue 10, pp. 1232-1237, Oct 2017.
Browse journals by subject